mRNA vaccines are a novel vaccine technology that deliver mRNA encoding the antigen protein of a pathogen. This allows the antigen protein to be expressed by the recipient's cells and stimulate an immune response. There are two main types of mRNA vaccines - non-replicating mRNA and self-amplifying mRNA. Delivery strategies include viral carriers like lentivirus or non-viral carriers like liposomes. Administration routes include intramuscular injection, intradermal injection, and intranodal injection. Creative Biolabs offers several mRNA vaccine platforms including non-replicating mRNA vaccines, self-amplifying mRNA vaccines, and dendritic cell mRNA vaccines.
This slide tries to explain and introduce you to the mRNA Vaccine Technology, describes mRNA Vaccines, Mechanism , Delivery, some research and case study of pandemic and advantages disadvantages & application see for yourself in detail.
Unlocking the Potential of mRNA Vaccines and TherapeuticsMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3lNmkf7
The therapeutic potential of mRNA has been studied for decades and this exciting modality could potentially disrupt the biological market, in particular vaccine and novel therapies. This webinar will highlight the potential of mRNA therapies and focus on the manufacturing process's associated challenges, solutions and perspectives from synthesis to delivery.
mRNA has emerged as a promising modality for a wide range of therapeutics and vaccines and could become the break-through technology of this century. mRNA-based platform technologies could enable a more rapid response to infectious diseases, outbreaks or pandemics and allow efficient gene replacements or cancer treatments. mRNA represents a safer alternative to DNA-based therapies and the technology has recently advanced to overcome stability and efficacy challenges. Because of that, the industrialization of this technology is just in its infancy stages and bottlenecks exist around scalability, purity, and delivery which are key to establish and deliver the promise of such platform. This webinar will shed light on the potential of mRNA therapies and focus on the manufacturing process's associated challenges, solutions and perspectives from synthesis to delivery.
In this webinar, you will learn:
• The potential behind using mRNA as a therapeutic and vaccine
• The mRNA production process
• The challenges around mRNA production
• The solutions and perspectives for a robust manufacturing process
• mRNA delivery systems and their manufacturing
IntegrateRNA provides custom mRNA synthesis and modification service by in vitro transcription and chemical synthesis. https://integraterna.creative-biogene.com/service/mrna-services.html
mRNA vaccine is a novel vaccine technology, which delivers mRNA that encoding the antigen protein of pathogen to the cell, and expresses the antigen protein, and then stimulates the immune response of the body.
Creative Biolabs has developed non-replicating mRNA vaccine platform, mRNA vaccine platform, mRNA pharmacology optimization platform, and and Self-amplifying mRNA vaccine platform to spport your vaccine researches. If you need more information about mRNA vaccine, please follow us.
In this presentation, I talked about the new mRNA vaccine that is authorized for the prevention of coronavirus infection.
mRNA 1273 is developed by Moderna in the US and has shown almost 94% effectiveness
DNA vaccines (types, method and mechanism) Aneela Rafiq
DNA Vaccine is very promising method in current century. it can eliminate the risks of encountering pathogen with living cell.
this presentation has a brief concept about DNA Vaccine, to understand the baseline of genetic vaccine.
This slide tries to explain and introduce you to the mRNA Vaccine Technology, describes mRNA Vaccines, Mechanism , Delivery, some research and case study of pandemic and advantages disadvantages & application see for yourself in detail.
Unlocking the Potential of mRNA Vaccines and TherapeuticsMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3lNmkf7
The therapeutic potential of mRNA has been studied for decades and this exciting modality could potentially disrupt the biological market, in particular vaccine and novel therapies. This webinar will highlight the potential of mRNA therapies and focus on the manufacturing process's associated challenges, solutions and perspectives from synthesis to delivery.
mRNA has emerged as a promising modality for a wide range of therapeutics and vaccines and could become the break-through technology of this century. mRNA-based platform technologies could enable a more rapid response to infectious diseases, outbreaks or pandemics and allow efficient gene replacements or cancer treatments. mRNA represents a safer alternative to DNA-based therapies and the technology has recently advanced to overcome stability and efficacy challenges. Because of that, the industrialization of this technology is just in its infancy stages and bottlenecks exist around scalability, purity, and delivery which are key to establish and deliver the promise of such platform. This webinar will shed light on the potential of mRNA therapies and focus on the manufacturing process's associated challenges, solutions and perspectives from synthesis to delivery.
In this webinar, you will learn:
• The potential behind using mRNA as a therapeutic and vaccine
• The mRNA production process
• The challenges around mRNA production
• The solutions and perspectives for a robust manufacturing process
• mRNA delivery systems and their manufacturing
IntegrateRNA provides custom mRNA synthesis and modification service by in vitro transcription and chemical synthesis. https://integraterna.creative-biogene.com/service/mrna-services.html
mRNA vaccine is a novel vaccine technology, which delivers mRNA that encoding the antigen protein of pathogen to the cell, and expresses the antigen protein, and then stimulates the immune response of the body.
Creative Biolabs has developed non-replicating mRNA vaccine platform, mRNA vaccine platform, mRNA pharmacology optimization platform, and and Self-amplifying mRNA vaccine platform to spport your vaccine researches. If you need more information about mRNA vaccine, please follow us.
In this presentation, I talked about the new mRNA vaccine that is authorized for the prevention of coronavirus infection.
mRNA 1273 is developed by Moderna in the US and has shown almost 94% effectiveness
DNA vaccines (types, method and mechanism) Aneela Rafiq
DNA Vaccine is very promising method in current century. it can eliminate the risks of encountering pathogen with living cell.
this presentation has a brief concept about DNA Vaccine, to understand the baseline of genetic vaccine.
mRNA rather than DNA may become the nucleotide framework for new classes of drugs and vaccines. Exciting preclinical results in prophylaxis and initial clinical data in oncology suggest that mRNA technology could be translated into improvements in lung cancer and other diseases.
It is very fast and new technique for detection and degradation of viral DNA and it is so helpful for us to understand how to degraded viral DNA... what type of function naturally present in bacteria........ so its very excellent technique
Developing vaccines against infectious and epidemic diseases with the aid of Bioinformatics is now possible, by predicting epitopes on an antigen and finding possible targets for the antibody to bind. A new era of vaccine production is just ahead of us.
Watch out the ppt to know more!!!
vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future.
HISTORY OF VACCINES-
EDWARD JENNER conduct experiments in 1796 that lead to the creation of the first smallpox vaccine for prevention of smallpox.
A vaccine for RABIES is developed by LOUIS PASTEUR .
Vaccine for COLERA and TYPHOID were developed in 1896 and PLAGE vaccine in 1887.
The first DIPHTHERIA vaccine is developed in about 1913 by EMIL ADOLPH BEHRING,WILLIAM HALLOCK PARK.
The whole cell PERTUSIS vaccines are developed in 1914.
A TETANUS vaccine is developed in 1927.
SYNTHETIC PEPTIDE VACCINES AND RECOMBINANT ANTIGEN VACCINED.R. Chandravanshi
What is a Vaccine?
A vaccine is a substance that is introduced into the body to prevent infection or to control disease due to a certain pathogen (a disease-causing organism, such as a virus, bacteria or parasite). The vaccine “teaches” the body how to defend itself against the pathogen by creating an immune response.
1 Unlike traditional pharmaceuticals, vaccines are biologics since they are made from living organisms (biological sources).
2 Specifically, vaccines are preparations of components derived from (or related to) a pathogen; they can typically induce a protective effect through one to three very small doses, in the range of micrograms to milligrams.
3 Immunity lasts for an extended period, from one year up to lifetime protection, including prevention of disease and/or related sequelae.
Synthetic peptide vaccines represent fragments of protein antigen sequences, synthesizing specific B cell and T cell epitopes offer the potential to induce diseases neutralizing immuno response with completely synthetic structure. Now it is well established that short chain peptides can be used to mimic antigenic sites of viruses and thus can be used the basics for vaccines and development. therefore, attempts have been made to synthesize such peptides which act as the serrogate immuunogens, as an alternative to the existing conventional vaccines.
i explained about basics of genome engineering and crispr system.
CRISPR will change the world and it is just the beginning, are you ready to meet the future? you think its great and beautiful or.....?
please give your feedback to my email
pooyanaghshbandi@yahoo.com
i am starting to write a critical and fantastic review article about CRISPR, if you are interested to join please contact me.
mRNA vaccines against emerging infectious diseases; A challenging approach of...AI Publications
Basic human biology is dealt with by mRNA, which creates instructions for making proteins that may aid in the fight against infectious illnesses using our bodies' own mechanisms. mRNA therapies are neither tiny compounds nor huge biological such as recombinant proteins or monoclonal antibodies. These are a series of instructions that assist our cells' machinery in producing proteins that protect us against a certain virus. Our bodies would be unable to perform their activities if mRNA was not introduced. mRNA, or messenger ribonucleic acid, is an important component of the living world, especially in the process of protein synthesis. mRNA is a single-stranded molecule that transmits genetic instructions from a cell's nucleus DNA to the ribosomes, which are the cell's protein-making machinery. The synthesis of an RNA copy from the coded sequence of DNA leads in the production of a particular protein. This copy of mRNA moves from the nucleus of the cell to the cytoplasm, where ribosomes reside. Ribosomes are a sort of sophisticated machinery organelle that aids and begins protein synthesis in cells. Ribosomes ‘read' the mRNA sequence and follow the instructions, progressively adding on various needed amino acids to make the intended protein during the translation process. The protein is subsequently expressed by the cell, and it goes on to execute its role in the cell or in the body. The use of mRNA as a medication offers up a whole new universe of possibilities in terms of illness treatment and prevention. This review contributes to the growing body of knowledge in the field of mRNA therapeutic delivery and the identification of appropriate antigens for mRNA target locations. Two major mRNA vaccines for protection against SARS-CoV-2 have recently been developed and approved for use in the general population by international health authorities. They've been demonstrated to defend against the SARS-CoV-2 virus, which is still active and evolving. This will draw attention to a variety of mRNA vaccines now being evaluated for infectious diseases in clinical studies. mRNA vaccines offer a number of advantages, including speedy design, fabrication, manufacturing, and administration, and they hold a lot of potential for future use against a wide range of diseases.
mRNA rather than DNA may become the nucleotide framework for new classes of drugs and vaccines. Exciting preclinical results in prophylaxis and initial clinical data in oncology suggest that mRNA technology could be translated into improvements in lung cancer and other diseases.
It is very fast and new technique for detection and degradation of viral DNA and it is so helpful for us to understand how to degraded viral DNA... what type of function naturally present in bacteria........ so its very excellent technique
Developing vaccines against infectious and epidemic diseases with the aid of Bioinformatics is now possible, by predicting epitopes on an antigen and finding possible targets for the antibody to bind. A new era of vaccine production is just ahead of us.
Watch out the ppt to know more!!!
vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future.
HISTORY OF VACCINES-
EDWARD JENNER conduct experiments in 1796 that lead to the creation of the first smallpox vaccine for prevention of smallpox.
A vaccine for RABIES is developed by LOUIS PASTEUR .
Vaccine for COLERA and TYPHOID were developed in 1896 and PLAGE vaccine in 1887.
The first DIPHTHERIA vaccine is developed in about 1913 by EMIL ADOLPH BEHRING,WILLIAM HALLOCK PARK.
The whole cell PERTUSIS vaccines are developed in 1914.
A TETANUS vaccine is developed in 1927.
SYNTHETIC PEPTIDE VACCINES AND RECOMBINANT ANTIGEN VACCINED.R. Chandravanshi
What is a Vaccine?
A vaccine is a substance that is introduced into the body to prevent infection or to control disease due to a certain pathogen (a disease-causing organism, such as a virus, bacteria or parasite). The vaccine “teaches” the body how to defend itself against the pathogen by creating an immune response.
1 Unlike traditional pharmaceuticals, vaccines are biologics since they are made from living organisms (biological sources).
2 Specifically, vaccines are preparations of components derived from (or related to) a pathogen; they can typically induce a protective effect through one to three very small doses, in the range of micrograms to milligrams.
3 Immunity lasts for an extended period, from one year up to lifetime protection, including prevention of disease and/or related sequelae.
Synthetic peptide vaccines represent fragments of protein antigen sequences, synthesizing specific B cell and T cell epitopes offer the potential to induce diseases neutralizing immuno response with completely synthetic structure. Now it is well established that short chain peptides can be used to mimic antigenic sites of viruses and thus can be used the basics for vaccines and development. therefore, attempts have been made to synthesize such peptides which act as the serrogate immuunogens, as an alternative to the existing conventional vaccines.
i explained about basics of genome engineering and crispr system.
CRISPR will change the world and it is just the beginning, are you ready to meet the future? you think its great and beautiful or.....?
please give your feedback to my email
pooyanaghshbandi@yahoo.com
i am starting to write a critical and fantastic review article about CRISPR, if you are interested to join please contact me.
mRNA vaccines against emerging infectious diseases; A challenging approach of...AI Publications
Basic human biology is dealt with by mRNA, which creates instructions for making proteins that may aid in the fight against infectious illnesses using our bodies' own mechanisms. mRNA therapies are neither tiny compounds nor huge biological such as recombinant proteins or monoclonal antibodies. These are a series of instructions that assist our cells' machinery in producing proteins that protect us against a certain virus. Our bodies would be unable to perform their activities if mRNA was not introduced. mRNA, or messenger ribonucleic acid, is an important component of the living world, especially in the process of protein synthesis. mRNA is a single-stranded molecule that transmits genetic instructions from a cell's nucleus DNA to the ribosomes, which are the cell's protein-making machinery. The synthesis of an RNA copy from the coded sequence of DNA leads in the production of a particular protein. This copy of mRNA moves from the nucleus of the cell to the cytoplasm, where ribosomes reside. Ribosomes are a sort of sophisticated machinery organelle that aids and begins protein synthesis in cells. Ribosomes ‘read' the mRNA sequence and follow the instructions, progressively adding on various needed amino acids to make the intended protein during the translation process. The protein is subsequently expressed by the cell, and it goes on to execute its role in the cell or in the body. The use of mRNA as a medication offers up a whole new universe of possibilities in terms of illness treatment and prevention. This review contributes to the growing body of knowledge in the field of mRNA therapeutic delivery and the identification of appropriate antigens for mRNA target locations. Two major mRNA vaccines for protection against SARS-CoV-2 have recently been developed and approved for use in the general population by international health authorities. They've been demonstrated to defend against the SARS-CoV-2 virus, which is still active and evolving. This will draw attention to a variety of mRNA vaccines now being evaluated for infectious diseases in clinical studies. mRNA vaccines offer a number of advantages, including speedy design, fabrication, manufacturing, and administration, and they hold a lot of potential for future use against a wide range of diseases.
This slide is about the basics of mRNA-based therapy. The content includes: definition of mRNA, timeline of mRNA therapeutics, action mechanism and development strategies of mRNA drugs, therapeutic mRNA applications, and the related services provided by Creative Biolabs.
This slide provides a comprehensive overview of lipid nanoparticle-based mRNA Vaccine development, detailing the technological timeline, the 2023 Nobel Prize-winning science behind the vaccines, and the specifics of COVID-19 vaccine candidates BNT162b2 and mRNA-1273. It also explores the advantages of liposomes in mRNA delivery, the intricate mechanisms of LNP-based vaccines, their therapeutic potential beyond COVID-19, and the rigorous development process. Creative Biolabs supports these innovations with specialized services and products, pushing the boundaries of medical science.
The core principle behind mRNA as a technology for vaccination is to deliver the transcript of interest, encoding one or more immunogen(s) into the host cell cytoplasm where expression generates translated protein(s) are ultimately located in the membrane, to be secreted, or intracellular. Two categories of mRNA constructs are being evaluated: non-replicating mRNA (NRM) and self-amplifying mRNA (SAM).
https://www.creative-biolabs.com/lipid-based-delivery/
coronavirus caused millions of deaths around the world recently .
not only knowing the structure of this virus matters but also the vaccines preventing its deadly effects is of importance .
in this power point which I prepared for my university advisor almost 1.5 year ago I mentioned all types of vaccines which then were approved or were on clinical trials.
Prospects And Future Trend of mRNA Therapeutics.pdfDoriaFang
The great success of the mRNA COVID-19 vaccines have revived interest in using mRNA to express therapeutic proteins. In addition to the mRNA COVID-19 vaccine, a series of clinical trials have begun using mRNA to express vascular endothelial growth factor (VEGF) to treat heart failure, and CRISPR-Cas9 mRNA to treat rare genetic diseases.
Recombinant viral vectors are genetic engineering tools commonly used for gene transfer purpose with high transfection efficiency and site specific gene insertion.
Viral Based Gene Delivery System for Car-t Cell Engineering Creative-Biolabs
A brief introduction about lentiviral vector gene delivery system and its application in CAR-T cell construction. Creative Biolabs offers high quality lentivirus based CAR gene delivery service to help with your CAR-T cell development projects.
Plasmid Manufacturing Service from GenScript ProBioGenScript ProBio
GenScript ProBio offers the best Plasmid Manufacturing Service and employs a GMP-compliant plasmid production process that allows customers to replicate DNA used in experiments with minimal additional effort. By employing this process, Genscript can provide plasmids produced at the highest quality standards. For more information, visit our website. https://www.genscriptprobio.com/gct-proplasmid.html
Vaccine discovery
DNA vaccine, mechanism
methods of delivery
Main concerns: do DNA vaccines cause insertional mutation and elicit anti-DNA antibodies in the body?
completed and ongoing trials.
new strategies: Prime Boost vaccines
Future prospects
Recently, the development of molecular biotechnology allows modifications of viral genomes genetically and optimizes the transformation of available viruses with weak pathogenicity. These methods are used to enhance the oncolytic effect and reduce adverse reactions to maximize both efficacy and safety. Indeed, the oncolytic virus can stimulate a pro-inflammatory tumor environment by enhancing antigen recognition and robust immune responses. It overcomes the immune evasiveness and escape of malignant cells to eliminate the tumor cells.
https://www.creative-biolabs.com/oncolytic-virus/definition-of-an-oncolytic-virus.htm
An oncolytic virus is a form of promising therapeutic tool for the treatment of malignant tumors, which uses viruses to selectively infect and kill tumor cells and further to induce or boost specific antitumor immunity. https://www.creative-biolabs.com/oncolytic-virus/definition-of-an-oncolytic-virus.htm
Oncolytic viruses encoding reporter genes utilized for in vivo molecular imaging are useful to locate the distribution of oncolytic viruses in pre-clinical tests. Optical detection methods mainly include green fluorescent protein (GFP), enhanced GFP (eGFP), discosoma red fluorescent protein (DsRed), and bioluminescence imaging (BLI), which utilizes luciferases. Reporter-encoding oncolytic viruses, including vaccinia virus, adenovirus, herpes simplex virus and vesicular stomatitis virus, allow accurate tracking of gene expression, tumor metastases, viral infection as well as assessment of gene therapy.
https://www.creative-biolabs.com/oncolytic-virus/category-reporter-encoding-oncolytic-virus-293.htm
Vaccinia virus can accommodate more than 30 kb of foreign DNA. Foreign genes can be stably integrated into the viral genome, resulting in efficient and long-term gene expression. The deletion of the viral genes of thymidine kinase (TK) and vaccinia growth factors (VGF) results in enhanced tumor-selectively and antitumor activity, and reduced virus virulence. https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-vaccinia-virus-291.htm
Oncolytic viruses are a class of antitumor agents that selectively kill tumor cells without affecting normal cells. Vaccinia virus (VACV) is a large, enveloped virus that is considered as the most potential live biotherapeutic agent because of its strong oncolytic efficacy and potent antigen presentation capability that can combine well with its natural oncolytic activities for cancer immunotherapy. Many types of modified vaccinia virus have been used for in vitro and in vivo studies, as well as clinical trials.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-vaccinia-virus-291.htm
Partial deletion of the HSV gene results in superior packaging capacity of >30 kb foreign DNA with low toxicity as an expression vector. Multiple modified purified oncolytic herpes simplex virus (oHSV) products can avoid evading the host immune response and reduce toxicity by gene knock-out, such as ICP0, ICP4, ICP22, ICP27 or ICP47.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-herpes-simplex-virus-290.htm
Oncolytic viruses are using for the treatment of cancer due to the specific antitumor activity in tumor cells. Herpes simplex virus (HSV) is a human neurogenic dsDNA virus that has the characteristic of life-long latent infection of neurons and allows for long-term transgene expression.https://www.creative-biolabs.com/oncolytic-virus/category-pre-made-oncolytic-herpes-simplex-virus-290.htm
Oncolytic viruses have the potential to powerfully and selectively kill cancer cells and have shown impressive efficacy in preclinical and clinical settings. However, their potential can be restricted by inefficient delivery into the complex tumor environment. Thus, the efficient delivery of oncolytic viruses remains a significant challenge in the field of oncology, limiting their therapeutic effect. https://www.creative-biolabs.com/oncolytic-virus/approaches-to-delivery-of-oncolytic-viruses.htm
Numerous viruses are being developed pre-clinically and clinically. An investigation of all registered clinical trials in 2017 demonstrates 78 interventional trials regarding OVs. This ability for near-universal therapeutic impact in cancer makes OVs a popular therapeutic tool. Today, both preclinical and early-stage clinical trials are intensively investigating the approach to improve oncolytic virotherapy.
https://www.creative-biolabs.com/oncolytic-virus/applications-of-oncolytic-viruses-in-cancer-treatment.htm
To fully optimize oncolytic virotherapy and provide meaningful mechanistic insight, it is important to have representative animal models of oncolysis in various tumor types. https://www.creative-biolabs.com/oncolytic-virus/animal-models-for-oncolytic-virus-study.htm
Abciximab (also known as abcixifiban or c7E3 Fab), is the Fab fragment of the chimeric human-murine, monoclonal antibody 7E3. It is composed of murine variable regions and human constant regions.https://www.creativebiolabs.net/abciximab-overview.htm
Abagovomab is a murine monoclonal anti-idiotypic antibody (MW: 165-175 kDa), produced by a mouse hybridoma and generated against OC125, which serves to functionally imitate the human cancer antigen 125 (CA-125). https://www.creativebiolabs.net/abagovomab-overview.htm
Wnt comprises a diverse family of secreted lipid-modified signaling glycoproteins that are 350-400 amino acids in length. Wnt is an acronym in the field of genetics that stands for 'Wingless/Integrated'.https://www.creativebiolabs.net/wnt-signaling-pathway.htm
TNF works through two receptors, TNFR1 and TNFR2. TNFR1 is the major signal receptor of TNF-α. TNFR2, which mediates limited biological responses, binds to TNF-α and TNF-β. TNF signaling transduction through TNFR1 and TNFR2 can induce a variety of cellular responses, which depends on many factors, including the metabolic state of the cell and the adaptor proteins present in the cell.https://www.creativebiolabs.net/tnf-signaling-pathway.htm
Innate immune receptors, also known as pattern recognition receptors (PRRs), have been identified in the serum, on the cell surface, in endosomes, and in the cytoplasm. Toll-like receptors (TLRs) is one of the particularly important groups of PRRs.https://www.creativebiolabs.net/tlr-signal-pathway.htm
Transforming growth factor beta (TGF-β) is a cytokine that participates in both physiological and pathological processes.https://www.creativebiolabs.net/tgf-beta-signaling-pathway.htm
T-cell receptor (TCR) is a heterodimers composed of α and β peptide chains. TCR is mainly responsible for recognizing the antigens presented by major histocompatibility complex (MHC) molecules on the surface of antigen presenting cells (APC).https://www.creativebiolabs.net/tcr-signal-pathway.htm
Ras, which is a low-molecular-weight GDP/GTP-binding guanine triphosphatase, is the prototypical member of the Ras superfamily of proteins. https://www.creativebiolabs.net/ras-signaling-pathway.htm
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, which are responsible for regulating gene expression.https://www.creativebiolabs.net/ppar-signaling-pathway.htm
PI3K-Akt signaling pathway is one of the important signal transduction pathways in cells. It is involved in regulating cell metabolism, growth, proliferation, survival, transcription and protein synthesis by affecting the activation of downstream effector molecules. https://www.creativebiolabs.net/pi3k-akt-signaling-pathway.htm
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
1. A brief introduction of a novel vaccine technology
mRNA Vaccine
Address: 45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-biolabs.com
Web: www.creative-biolabs.com
2. Contents
mRNA and mRNA vaccine
1
Characteristics of mRNA vaccine
2
Mechanism of action of mRNA-based vaccines
3
Types of mRNA vaccine
4
Delivery strategies of mRNA vaccine
5
Administration routes for mRNA vaccines
6
Creative Biolabs’ mRNA vaccine platforms
7
3. What is mRNA and mRNA vaccine?
Messenger RNA(mRNA)
• Responsible for transferring genetic
information from DNA to protein
mRNA Vaccine
• A novel vaccine technology which
delivers the mRNA that encoding the
antigen protein of pathogen to the cell,
expresses the antigen protein, and then
stimulates the immune response of the
body.
• A template for protein translation
4. Characteristics of mRNA Vaccine
Types Immuno-
genicity
Safety Antibody
specificity
Composition manufactur
e
R&D
cycle
immune
response
Application
Attenuated/
inactivated
vaccine
Strong Low low Not clear simple 8 years+ Cellular
immunity;
Humoral
immunity
Prophylactic
vaccine
Subunit
vaccine
weak High high clear Complicate
d
8 years+ Cellular
immunity
or Humoral
immunity
Therapeutic
vaccine;
Prophylactic
vaccine
DNA
vaccine
weak Controversial low clear simple 3~5
years
Cellular
immunity;
Humoral
immunity
Therapeutic
vaccine;
Prophylactic
vaccine
mRNA
vaccine
Strong High high clear simple 3~5
years
Comparison among characteristics of different vaccine types
5. Mechanism of Action of mRNA-Based Vaccine
mRNA encapsulated in the delivery vehicle is
taken up by APC cell.
(Opportunities and Challenges in the Delivery of mRNA-based vaccine)
Delivery vehicle is digested, and mRNA released.
mRNA is translated by the host’s ribosome and
antigen is formed.
After the antigen is formed, it can be processed
through different pathways.
1
2
3
4
6. Types of mRNA vaccine
Non-replicating mRNA
Self-amplifying mRNA
Regulatory elements in 5'U T R and 3'U T R stabilize
mRNA and increase antigen protein translation.
5’-G
Cap enables mRNA to
translate in the right
direction.
Poly A can increase the mRNA
stability and the expression of antigen
protein, playing an important role in
the translation and stability of mRNA.
P P P UTR SP ORF UTR AAAAAA(140-150)-3’
CAP 5‘Untranslated Region 3‘Untranslated Region Poly A Tail
Open Reading Frame
Open reading frame is a nucleic acid
sequence that encodes antigens.
7. Non-replicating mRNA
Self-amplifying mRNA
Non-structural genes for
self-amplification.
Virus-derived self-amplifying mRNA is
to insert the nucleic acid sequence
encoding antigen directly into single-
stranded RNA virus, such as Semliki
forest virus, yellow fever virus, etc.
5’-G P P P UTR nsP4
ORF UTR AAAAAA(140-150)-3’
nsP3 nsP2 nsP1
SP
CAP 5‘Untranslated Region
Insert Fragment
CAP 3‘ Untranslated Region Poly A Tail
Types of mRNA vaccine
9. 1
2
3
4
Liposome delivery mRNA has unique advantages
Liposomes are spherical vesicles, which can encapsulate mRNA
to resist the action of nuclease;
Liposomes are similar to cell membrane and are easy to fuse
with recipient cells, and the transfection efficiency is high;
Liposomes can deliver different sizes of mRNA;
Liposomes as delivery carriers are not restricted by the host.
Up until now, lipid vectors have become the most effective
non-viral vectors for delivering mRNA.
Delivery Strategies of mRNA Vaccine
10. mRNA vaccines can be delivered without any additional carriers, that is, in a naked
format. In this method, mRNA is dissolved in buffer and then injected directly.
Advantages:
1. Easy to store and prepare. In the presence of storage reagents
such as 10% trehalose, freeze-dried naked RNA can remain stable
for up to 10 months at 4℃.
2. Vaccines made from unmodified nucleotides have dual
advantages in innate immunogenicity. Immunogenicity may be
beneficial to vaccination by providing some adjuvant activity. On
the other hand, the activation of some RNA sensors may inhibit
mRNA translation in the cytoplasm.
Naked mRNA Vaccines
Delivery Strategies of mRNA Vaccine
11. Delivery Strategies of mRNA Vaccine
Autologous DC from primary human PBMCs is the main
source for the preparation of mRNA-treated DC for in vivo
applications. The main strategies for the transmission of
mRNA to DC are electroporation and lipid-derived carriers.
Advantages:
1. Effective APC is essential for innate / adaptive immunity.
2. Biocompatibility
DC-Based mRNA Vaccines
12. Administration Routes for mRNA Vaccines
(Formulation and Delivery Technologies for mRNA Vaccines)
Deliver mRNA vaccine directly
into the dermis and make it
extracted by APC cells.
Have a larger injection
volume and reduce local
adverse reactions.
Main injection routes include intradermal (ID) injection, subcutaneous (SC) injection, intramuscular (IM)
injection, nodule (IN) injection and intravenous (IV) injection.
Send mRNA vaccine directly
into APC and lymphoid
organs.
Recruit different types of
immune cells and recycle
them to the injection site.
APC in the lymphoid organs can
easily phagocytize the injected
mRNA vaccine, which improves
the efficacy of the vaccine.
Intradermal Injection Subcutaneous Injection Intravenous Injection Intramuscular Injection Intranodal Injection
The disadvantage is that it has
local side effects, and the
injection volume is limited.
The absorption rate of SC
region is very slow, which
may lead to accidental
degradation of mRNA
vaccine.
mRNA can be easily
degraded through this
routes.
The local reaction of
intramuscular injection is
mild, but the injection
volume is limited.
The vaccination
procedure is complicated.
13. Creative Biolabs’ mRNA Vaccine Platform
mRNA Vaccine Platform
Dendritic Cell mRNA
Vaccines
Personalized Neoepitope
mRNA Cancer Vaccines
mRNA GMP Synthesis
Non-replicating mRNA Vaccine Platform
Non-replicating mRNA
vaccines
mRNA Pharmacology Optimization Platform
Optimization Service of
mRNA Translation and
Stability
Services of Immunogenicity
Modulation
Effective mRNA Delivery
Service
Self-amplifying mRNA
(SAM) Vaccine Platform
SAM vaccine design
Synthesis of SAM vaccine
Optimization of SAM vaccines
Preclinical evaluation of SAM
vaccine
CREATIVE
BIOLABS
14. mRNA Vaccine
Address: 45-1 Ramsey Road, Shirley, NY 11967, USA
Email: info@creative-biolabs.com
Web: www.creative-biolabs.com